Abstract
Background Cardiovascular disease (CVD) and cancer share several risk factors. While preclinical models show that various types of CVD can accelerate cancer progression, clinical studies have not determined the impact of atherosclerosis on cancer risk.
Objectives To determine whether CVD, especially atherosclerotic CVD, is independently associated with incident cancer.
Methods Using IBM MarketScan claims data from over 130 million individuals, we identified 27 million cancer-free subjects with a minimum of 36 months of follow-up data. Individuals were stratified by presence or absence of CVD, with 1:1 propensity matching to control for cardiovascular risk factors, and cumulative risk of cancer was calculated. Additional analyses were performed according to CVD type (atherosclerotic vs non-atherosclerotic) and cancer subtype.
Results Among 4,487,412 matched individuals, those with CVD had a 1.26-fold higher relative risk of cancer than those without CVD (6.8% vs 5.4% 5-year cumulative incidence). Results were more pronounced for individuals with atherosclerotic CVD (aCVD), who had a 1.43-fold higher relative risk than those without CVD (7.7% 5-year cumulative cancer incidence). Findings persisted after multivariable adjustment for numerous traditional CV risk factors, including the modestly higher risk for cancer amongst individuals with atherosclerotic CVD. Cancer subtype analyses showed specific associations of aCVD with several malignancies, including lung, bladder, liver, brain, and other hematologic cancers.
Conclusions Individuals with CVD have an increased risk of developing cancer compared to those without CVD. This association may be driven in part by the relationship of atherosclerosis with specific cancer subtypes, which persists after controlling for conventional risk factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Bell has received an unrestricted grant from Damon Runyon Cancer Research Foundation PST 33-21 for the conduct of this study. This research was supported, in part, by National Institutes of Health CCSG P30 CA016672. Dr. Nead and Dr. Wehner are Cancer Prevention and Research Institute of Texas (CPRIT) Scholars in Cancer Research. Dr. Nead is supported by CPRIT RR190077, NCI L30CA253796, and NCI K08CA263313. Dr. Wehner is supported by CPRIT FP9178. Dr. Giordano is supported by CPRIT RP160674 and Komen SAC150061. Dr. Leeper is supported by NIH R35HL144475 and AHA EIA34770065.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approved at MD Anderson Cancer Center
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: Dr. Bell has received an unrestricted grant from Damon Runyon Cancer Research Foundation PST 33-21 for the conduct of this study. This research was supported, in part, by National Institutes of Health CCSG P30 CA016672. Dr. Nead and Dr. Wehner are Cancer Prevention and Research Institute of Texas (CPRIT) Scholars in Cancer Research. Dr. Nead is supported by CPRIT RR190077, NCI L30CA253796, and NCI K08CA263313. Dr. Wehner is supported by CPRIT FP9178. Dr. Giordano is supported by CPRIT RP160674 and Komen SAC150061. Dr. Leeper is supported by NIH R35HL144475 and AHA EIA34770065.
Disclosures: The authors have no interests to declare.
Data Availability
Data are available through the vendor on investigator application
Abbreviation List
- CVD
- cardiovascular disease
- aCVD
- atherosclerotic cardiovascular disease
- naCVD
- nonatherosclerotic cardiovascular disease
- HRA
- health risk assessment
- PS
- propensity score
